Literature DB >> 8880019

Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment.

K O Pietilä1, A P Harmoinen, J Jokiniitty, A I Pasternack.   

Abstract

OBJECTIVES: We studied the relationship between serum C-reactive protein and mortality in acute myocardial infarction.
BACKGROUND: Early recanalization of an infarct-related coronary artery is considered to be an essential prerequisite for reducing mortality by thrombolytic treatment in acute myocardial infarction. It also reduces the inflammatory reaction caused by acute myocardial infarction and is measurable by determination of serum C-reactive protein concentrations. We therefore studied the prognostic value of determining serum C-reactive protein in acute myocardial infarction.
METHODS: We measured serum C-reactive protein concentrations daily for 6 days and creatine kinase, as well as its MB isoenzyme concentrations twice a day, for 3 days after a myocardial infarct, in 188 consecutive patients selected for thrombolytic therapy and treated in the same University Hospital Coronary Care Unit. The highest serum concentrations were related to total mortality as well as to the causes of death 3, 3-6, 6-12 and 12-24 months after the onset of the myocardial infarction.
RESULTS: The highest serum concentrations of serum C-reactive protein were observed 2 to 4 days after the onset of myocardial infarction. The mean value of the highest serum concentration of C-reactive protein in patients who survived the whole 24-month study period was 65 mg. 1(-1), with the 95% confidence intervals for the mean ranging from 58 to 71. The corresponding values in those who died within 3, 3-6, 6-12 and 12-24 months were 166 (139-194), 136 (88-184), 85 (52-119) and 74 (38-111) mg.1(-1), respectively. The values in those who died within 3 and 3-6 months of the infarction differed statistically significantly from the values in those who survived the whole period (P < 0.001 and P < 0.05, respectively). In patients who died due to congestive heart failure the mean highest serum C-reactive protein concentration was 226 (189-265) mg.1(-1). In those who suffered sudden cardiac death and those who died from a new myocardial infarction or non-cardiac causes, the respective values were 167 (138-196), 64 (38-89) and 48 (10-86) mg. 1(-1). The values in those who died due to congestive heart failure and those suffering sudden cardiac death differed statistically significantly (P < 0.001) from the values of those who survived or died due to other causes. The highest serum concentrations of creatine kinase or its MB isoenzyme were not associated with mortality in this study.
CONCLUSIONS: High serum C-reactive protein concentrations in acute myocardial infarction patients treated with thrombolytic drugs predict increased mortality up to 6 months following the infarction. Accordingly, reduction of inflammatory reaction by successful thrombolytic treatment may make an important contribution to the survival benefit of thrombolytic treatment of acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880019     DOI: 10.1093/oxfordjournals.eurheartj.a015068

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  42 in total

1.  C reactive protein and acute phase of ischaemic stroke.

Authors:  M Di Napoli
Journal:  BMJ       Date:  2001-06-30

Review 2.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.

Authors:  K M Kulmatycki; K Abouchehade; S Sattari; F Jamali
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 4.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

5.  Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Authors:  Forough Sanaee; John D Clements; Alistair W G Waugh; Richard N Fedorak; Richard Lewanczuk; Fakhreddin Jamali
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

6.  Generation of C-reactive protein and complement components in atherosclerotic plaques.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

7.  Admission C-reactive protein and short- as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction.

Authors:  C Meisinger; M Heier; W von Scheidt; B Kuch
Journal:  Clin Res Cardiol       Date:  2010-07-02       Impact factor: 5.460

8.  Peri-infarct zone characterized by cardiac magnetic resonance imaging is directly associated with the inflammatory activity during acute phase myocardial infarction.

Authors:  Jose C Quinaglia e Silva; Otavio Rizzi Coelho-Filho; Joalbo M Andrade; Thiago Quinaglia; Rodrigo G P Modolo; Breno O Almeida; Rob J van der Geest; Michael Jerosch-Herold; Otavio Rizzi Coelho; Andrei C Sposito
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

9.  C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes.

Authors:  Uma Singh; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Clin Chem       Date:  2008-12-12       Impact factor: 8.327

10.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.